Answers are grounded in this paper and cite their sources.
Aims Lenvatinib (LEN) inhibits organic anion transporting polypeptide 1B1 (OATP1B1) in vitro, raising concern about drug–drug interactions (DDIs). We evaluated the in vivo impact of LEN on OATP1B activity in hepatocellular carcinoma (HCC), using coproporphyrin‐I (CP‐I) as endogenous biomarker. Methods Twenty‐six patients with HCC received LEN in this prospective, single‐centre, observational study. Plasma CP‐I and total and unbound LEN concentrations were measured at baseline and for 24 h after the first dose. DDI risk was assessed using the ICH M12 basic static model. Changes from baseline were analysed using a linear mixed‐effects model on log‐transformed concentrations with Dunnett's multiple comparisons and expressed as geometric mean ratios (GMR) with 95% confidence intervals (CIs). Results No significant changes in plasma CP‐I from baseline were observed at any time point, regardless of OATP1B1 genotype or hepatic function (adjusted p ≥ .25 in all comparisons). Whole‐cohort GMRs ranged from 0.97 to 1.11, with upper limit of 95% CI not exceeding 1.30. Baseline CP‐I did not differ by genotype ( p = .578) but was higher in Child–Pugh B than A ( p = .013). Using the basic static model, the median estimated C max ,inlet,u‐to‐IC 50 ,u ratio was 0.009, well below the 0.1 threshold. Conclusions LEN did not significantly alter OATP1B activity in HCC patients, concordant with static model prediction that first‐dose unbound LEN concentrations were far below the threshold for OATP1B1 inhibition. LEN‐attributable OATP1B1‐mediated DDI risk is therefore low, although this does not account for the reduced baseline OATP1B function inherent to HCC. Caution is warranted when extrapolating these findings to preserved hepatic function.
No takes yet. Share an insight, caveat, or question.
Shiraiwa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: